Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
Razonable, Raymund R. , Bishop, Rachel, Culbertson, Tracy L, Borgen, Molly Destro, Hedin, Michelle C., Hopkins, Laura H., Jackson, Tammy A., Larsen, Jennifer J., Matoush, Jennifer A., Moehnke, Darcie E. , Olson, Shelly M., Peterson, Kellie M, Rosedahl, Jordan K., Bishop, Rachel K, Destro Borgen, Molly, Moehnke, Darcie E , Rosedahl, Jordan, Razonable, Raymund R , Ganesh, Ravindra , Borgen, Molly J. Destro, Philpot, Lindsey M.

Mayo Clinic

Journal of Patient Experience | June 24, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23743735221105673 | PMID 35769314 Get It

Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19.
P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
Eyre, Toby A. , Shah, N. N., Dreyling, Martin, Wang, Y., Gandhi, M., Chay, C., Sharman, Jeff P. , Andorsky, David , Yin, Ming , Balbas, Minna, Kherani, Jennifer , Wang, M. L., Gouill, Steven Le , Vandenberghe, Elisabeth , Jurczak, Wojciech , Wang, Yucai , Cheah, Chan Y. , Yin, M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 990-991

10.1097/01.hs9.0000847268.67095.fc Get It

P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM
Al‐Kali, Aref , Borate, Uma , Cluzeau, Thomas , DeZern, A. E., Kobata, Kazuma, Lyons, Roger M. , Sallman, David A. , Xiao, Zhijian , Hoef, Marlies Van, Nourry-Boulot, Claire, Sadek, Islam Mohamad, IORDAN, Ana-Maria, Sabo, Jennifer L., Garcia‐Manero, G., Zeidan, Amer M. , Esteve, Jordi , Giagounidis, Aristoteles , Platzbecker, Uwe , Santini, Valeria , Sanz, Guillermo , Sekeres, Mikkael A. , Wei, Andrew H. , Ma, Fei

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 682-683

10.1097/01.hs9.0000846032.37876.c9 Get It

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY
Woyach, Jennifer A. , Eradat, Herbert, Brander, Danielle M. , Tees, Michael, Wang, W., Reddy, Nishitha , Farooqui, Mohammed, Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Byrd, John C. , Stephens, Deborah M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 578-579

10.1097/01.hs9.0000845612.25766.0c Get It

Association of Early and Late Hospital Readmissions with a Novel Housing-Based Socioeconomic Measure
Zurek, Kaitlyn I. , Boswell, Christopher L. , Miller, Nathanial E., Pecina, Jennifer L. , Decker, Matthew , Wi, Chung I., Garrison, Gregory M. , E Miller, Nathanial, L Pecina, Jennifer, I Wi, Chung, Pecina, Jennifer , Decker, Matthew D., Wi, Chung‐Il

Mayo Clinic

Health Services Research and Managerial Epidemiology | June 23, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23333928221104644 | PMID 35769114 Get It

Background While socioeconomic status has been linked to hospital readmissions for several conditions, reliable measures of individual socioeconomic status are often not available. HOUSES, a new measure of individual socioeconomic status based upon objective public data about one's housing unit, is inversely associated with overall hospitalization rate but it has not been studied with respect to readmissions. Purpose To determine if patients in the lowest HOUSES quartile are more likely to be readmitted within 30 days (short-term) and 180 days (long-term). Methods A retrospective cohort study of 11 993 patients having 21 633 admissions was conducted using generalized linear mixed-effects models. Results HOUSES quartile did not show any significant association with early readmission. However, when compared to the lowest HOUSES quartile, the second quartile (OR = 0.90, 95%CI 0.83-0.98) and the third quartile (OR = 0.91, 95%CI 0.83-0.99) were associated with lower odds of late readmission while the highest quartile (OR = 0.91, 95%CI 0.82-1.01) was not statistically different. Conclusion HOUSES was associated with late readmission, but not early readmission. This may be because early readmissions are influenced by medical conditions and hospital care while late readmissions are influenced by ambulatory care and home-based factors. Since HOUSES relies on public county assessor data, it is generally available and may be used to focus interventions on those at highest risk for late readmission.
Clinical and electrophysiological findings in C9ORF72 ALS
Sista, Sri Raghav, Shelly, Shahar , Oskarsson, Björn , Rubin, Devon I., Martinez‐Thompson, Jennifer M. , Parra‐Cantu, Carolina , Staff, Nathan P. , Laughlin, Ruple S. , Sista, Sri Raghav S , Oskarsson, Björn , Staff, Nathan P , Shahar, Shelly

Mayo Clinic

Muscle & Nerve | June 21, 2022 | Volume: 66 | Issue: 3 | Pages: 270-275

10.1002/mus.27665 | PMID 35727129 Get It

AbstractIntroduction/AimsAmyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disorder of motor neurons in which the cause is mostly unknown. Early identification of genetic ALS cases, of which C9ORF72 (C9ALS) is the most frequent, can have important implications for evaluation, prognosis, and therapeutics. Here, we aimed to characterize the clinical and electrophysiological hallmarks of C9ALS and investigate differences from C9ORF72 negative ALS (non‐C9ALS).MethodsWe retrospectively reviewed clinical and electrodiagnostic (EDX) data for all genetically confirmed C9ALS cases seen between 1/1/2012 and 10/1/2020 who met Gold Coast criteria and compared them 1:1 with non‐C9ALS patients within the same time frame.ResultsA total of 99 C9ALS and 99 non‐C9ALS cases were identified. Compared to non‐C9ALS, C9ALS demonstrated higher prevalence in women, lesser racial variability, stronger family history of ALS, and higher frequency of upper motor neuron signs. EDX testing of C9ALS showed higher median sensory nerve and lower fibular compound muscle action potential amplitudes.DiscussionAlthough the differences between C9ALS and non‐C9ALS reached statistical significance in certain nerve conduction parameters, they were not sufficient to discriminate between groups on a case‐by‐case basis. Genetic testing is required to identify C9ALS patients.
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies
Jung, Audrey , Ahearn, Thomas U. , Behrens, Sabine , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Arndt, Volker , Aronson, Kristan J. , Brenner, Hermann , Eriksson, Mikael , Evans, D. Gareth , Hadjisavvas, Andreas , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute , Hoppe, Reiner , Howell, Anthony , Hunter, David J. , Kosma, Veli‐Matti , Lissowska, Jolanta , Loizidou, Maria A. , Mannermaa, Arto , Maurer, Tabea, Olsson, Håkan , Patel, Alpa V , Perou, Charles M. , Shibli, Rana , Stone, Jennifer , Vachon, Celine M. , Wang, Sophia , Wu, Anna H. , Yang, Xiaohong R. , Zheng, Wei , Easton, Douglas F. , Chatterjee, Nilanjan , García‐Closas, Montserrat , Chang‐Claude, Jenny , Olsson, Håkan , Jung, Audrey Y , Becher, Heiko , Brenner, Hermann , Canzian, Federico , Czene, Kamila , Eliassen, A Heather , Figueroa, Jonine D , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G , Guénel, Pascal , Hadjisavvas, Andreas , Håkansson, Niclas , Hall, Per N , Hüsing, Anika , Koutros, Stella , Kraft, Peter , Marchand, Loïc Le , Lissowska, Jolanta , Loizidou, Maria A , Mannermaa, Arto , Murphy, Rachel A , Olsson, Håkan , Patel, Alpa V , Perou, Charles M , Shu, Xiao-Ou , Southey, Melissa C , Stone, Jennifer , Tamimi, Rulla M , Vachon, Celine M. , Wolk, Alicja , Dunning, Alison M , Pharoah, Paul D P , Easton, Doug , Milne, Roger L , Schmidt, Marjanka K , García-Closas, Montserrat , Chang-Claude, Jenny , Behrens, Sabine , Evans, D Gareth , Arndt, Volker , Kapoor, Pooja Middha , Zheng, Wei , Eriksson, Mikael , Wang, Sophia S , Wang, Qin , Augustinsson, Annelie , Freeman, Laura E. Beane , Becher, Heiko , Canzian, Federico , Carey, Lisa A. , Czene, Kamila , Eliassen, A. Heather , Figueroa, Jonine D. , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G. , Guénel, Pascal , Hopper, John L. , Hüsing, Anika , Kaaks, Rudolf , Koutros, Stella , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Murphy, Rachel A. , Olshan, Andrew F. , Rennert, Gad , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Teras, Lauren R. , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Dunning, Alison M. , Pharoah, Paul D.P. , Milne, Roger L. , Schmidt, Marjanka K.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 20, 2022 | Volume: 114 | Issue: 12 | Pages: 1706-1719

10.1093/jnci/djac117 | PMID 35723569 Get It

AbstractBackgroundReproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear.MethodsAnalyses included up to 23 353 cases and 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used to estimate the association between reproductive factors and risk of breast cancer by intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-HER2–like, HER2-enriched–like, and triple-negative breast cancer) and by invasiveness. All statistical tests were 2-sided.ResultsCompared with nulliparous women, parous women had a lower risk of luminal A-like, luminal B-like, luminal B-HER2–like, and HER2-enriched–like disease. This association was apparent only after approximately 10 years since last birth and became stronger with increasing time (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.49 to 0.71; and OR = 0.36, 95% CI = 0.28 to 0.46 for multiparous women with luminal A-like tumors 20 to less than 25 years after last birth and 45 to less than 50 years after last birth, respectively). In contrast, parous women had a higher risk of triple-negative breast cancer right after their last birth (for multiparous women: OR = 3.12, 95% CI = 2.02 to 4.83) that was attenuated with time but persisted for decades (OR = 1.03, 95% CI = 0.79 to 1.34, for multiparous women 25 to less than 30 years after last birth). Older age at first birth (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) and breastfeeding (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) were associated with lower risk of triple-negative breast cancer but not with other disease subtypes. Younger age at menarche was associated with higher risk of all subtypes; older age at menopause was associated with higher risk of luminal A-like but not triple-negative breast cancer. Associations for in situ tumors were similar to luminal A-like.ConclusionsThis large and comprehensive study demonstrates a distinct reproductive risk factor profile for triple-negative breast cancer compared with other subtypes, with implications for the understanding of disease etiology and risk prediction.
P36 Knowledge, attitudes, and awareness of contraceptive choices in women with inflammatory bowel disease
Liu, Eleanor , Erande, Aditi, Farraye, Jennifer , Cannon, Rachel , Limdi, Jimmy K. , Woodhams, Elisabeth J. , Farraye, Francis A.

Mayo Clinic

Poster presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A55.1-A55

10.1136/gutjnl-2022-bsg.96 Get It